OliX Pharmaceuticals (226950.KQ) Earnings Analysis
OliX Pharmaceuticals (226950.KQ) has no confirmed upcoming earnings date. Trailing P/E -188.91.
Last updated 2026-07-23 · Source: FMP fundamentals + earnings calendar (company filings); consensus from sell-side analyst grades
When does 226950.KQ next report earnings?
No confirmed upcoming earnings date is currently scheduled for 226950.KQ. This page updates as the calendar is published.
226950.KQ earnings history — beats and misses
| Quarter (report date) | EPS actual | EPS est. | Surprise | Result |
|---|---|---|---|---|
| 2026-03-16 | 762.35 KRW | n/a | n/a | n/a |
| 2025-05-15 | -708.83381 KRW | n/a | n/a | n/a |
| 2025-03-17 | -701.80918 KRW | n/a | n/a | n/a |
| 2024-11-14 | -621.00005 KRW | n/a | n/a | n/a |
226950.KQ valuation and analyst view
| Trailing P/E | -188.91 |
|---|---|
| Trailing EPS | -551.41593 KRW |
| Price / book | 17.47 |
| Dividend yield | 0.00% |
| Market cap | 2090.96B |
Limited or no published sell-side analyst coverage for this symbol.
Related research pages
Frequently asked questions
When is OliX Pharmaceuticals (226950.KQ)'s next earnings date?
No confirmed upcoming earnings date is currently scheduled for 226950.KQ. This page updates as the calendar is published.
Did 226950.KQ beat earnings last quarter?
Consensus estimate data was not available for 226950.KQ's 2026-03-16 report.
What is 226950.KQ's current P/E ratio and EPS?
226950.KQ trades at a trailing P/E of -188.91 on trailing EPS of -551.4159263519734 KRW.
What do analysts rate 226950.KQ?
226950.KQ has limited or no published sell-side analyst coverage in our dataset, so no consensus rating is shown. Fundamentals and earnings history above are sourced from company filings via FMP.